Pacritinib-d4

(Synonyms: SB1518-d4)
고객리뷰

Based on 1 Customer Validation

Pacritinib-d4 (SB1518-d4) is the deuterated-labeled Pacritinib (HY-16379). Pacritinib (SB1518) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity : 98.42%
  • 화학식: C28H28D4N4O3
  • 분자량:476.60
  • 보관:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Protocol
  • 순도&문서
  • References
  • Help & FAQs

All JAK Isoforms

More

All STAT Isoforms

More

All ERK Isoforms

More

All Akt Isoforms

More
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00